The burden of bladder cancer care: Direct and indirect costs

Current Opinion in Urology

Volumn 24, Issue 5, 2014, Pages 487-491

  Mossanen, Matthew ^a   Gore, John L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; cost; quality of care; quality of life

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; MITOMYCIN; VALRUBICIN;

BLADDER CANCER; CANCER PATIENT; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; FAMILY; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; TRANSURETHRAL RESECTION; UNITED STATES; COST OF ILLNESS; ECONOMICS; PSYCHOLOGY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

COST OF ILLNESS; CYSTOSCOPY; HEALTH CARE COSTS; HUMANS; QUALITY OF HEALTH CARE; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84905368142     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000078     Document Type: Review

References (51)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Cancer Facts Figures. American Cancer Society. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. [Accessed 18 March 2013]
3. Jones JS, Larchian WA. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh urology. In: Wein AJ, Kavoussi LR, Novick AC, et al. editors. 10th ed. Philadelphia: Saunders 2012; pp. 2335-2354.
4. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-653.
5. Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63: 36-44.
6. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012; 4: 13-32.
7. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-2330.
8. Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 2013; 49: 1889-1897.
9. Anastasiadis A, Cordeiro E, Bus MT, et al. Follow-up procedures for nonmuscle-invasive bladder cancer: an update. Expert Rev Anticancer Ther 2012; 12: 1229-1241.
10. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828-841.
11. Mariotto AB, Yabroff KR Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103:117-128.
12. Botteman MF. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmaco Economics 2003; 21: 1315-1330.
13. Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol 2007; 4: 147-154.
14. Svatek RS, Hollenbeck BK, Holmang S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014. doi: 10.1016/j.eururo.2014.01.006. [Epub ahead of print]
15. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-553.
16. Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000; 5: 87-92.
17. Hollenbeck BK, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009; 101: 571-580.
18. Green DA, Rink M, Cha EK, et al. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int 2013; 111(3 Pt B):E78-84.
19. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 2009; 27: 295-300.
20. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155: 1233-1238.
21. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171(6 Pt 1):2186-2190.
22. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-76.
23. Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166: 490-493.
24. Montie JE, Clark PE, Eisenberger MA, et al. Bladder cancer. J Natl Compr Canc Netw 2009; 7: 8-39.
25. Kilbridge KL, Kantoff P. Intravesical therapy for superficial bladder cancer: is it a wash?. J Clin Oncol 1994; 12: 1-4.
26. Marchetti A, Wang L, Magar R, et al. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000; 22: 422-438.
27. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66(6 Suppl 1):35-63.
28. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002; 167: 1634-1637.
29. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005; 173: 1108-1111.
30. Hemani ML, Makarov DV, Huang WC, Taneja SS. The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer. Cancer 2010; 116: 1264-1271.
31. Raitanen MP. The role of BTA stat Test in follow-up of patients with bladder cancer: results from Finn Bladder studies. World J Urol 2008; 26: 45-50.
32. Mian C, Pycha A, Wiener H, et al. A new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999; 161: 1486-1489.
33. Olsson H, Zackrisson B. Immuno Cyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001; 35: 280-282.
34. Kamat AM, Karam JA, Grossman HB, et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011; 108: 1119-1123.
35. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73.
36. Cauberg EC, Mamoulakis C, de la Rosette JJ, de Reijke TM. Narrow band imaging-assisted transurethral resection for nonmuscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol 2011; 29: 503-509.
37. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-1913.
38. Wood DP. Urothelial tumors of the bladder. Campbell-Walsh urology. In: Wein AJ, Kavoussi LR, Novick AC., editors. 10 ed. Philadelphia: Saunders, 2012; pp. 2309-2334.
39. Gilbert SM, Dunn RL, Hollenbeck BK, et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol 2010; 183: 1764-1769.
40. Gilbert SM, Wood DP, Dunn RL, et al. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007; 109: 1756-1762.
41. Cella DF. FACIT Manual. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales Version 4. Evanston, IL: Evanston Northwestern Healthcare and Northwestern University; 1997.
42. Sprangers MA, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998; 7: 291-300.
43. Allareddy V, Kennedy J, West MM, Konety BR. Quality of life in long-term survivors of bladder cancer. Cancer 2006; 106: 2355-2362.
44. Yoshimura K, Utsunomiya N, Ichioka K, et al. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology 2005; 65: 290-294.
45. Mack D, Frick J. Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. Br J Urol 1996; 78: 369-371.
46. Hemani ML, Bennett CL. The excessive cost of early stage bladder cancer care: are providers really to blame?. Cancer 2010; 116: 3530-3532.
47. Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009; 115: 2660-2670.
48. Chamie K, Saigal CS, Lai J, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011; 117: 5392-5401.
49. Lee CT, Barocas D, Globe DR, et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol 2012; 188: 2114-2119.
50. Hollingsworth JM, Zhang YS, Miller DC, et al. Identifying better practices for early-stage bladder cancer. Med Care 2011; 49: 1112-1117.
51. Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low risk superficial bladder tumors. J Urol 2008; 179: 87-90.